East Hanover, New Jersey 07936

  • Diabetic Retinopathy


The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.


Inclusion Criteria: - Males and females with type 1 and type 2 diabetes mellitus - Moderately severe or severe NPDR or mild PDR in at least one eye: - with an Early Treatment Diabetic Retinopathy Study (ETDRS) visual score of > 35 letters; and - not previously treated with scatter photocoagulation. - HbA1c < 13% at study entry Exclusion Criteria: - Condition which could interfere with the assessment of retinopathy progression - History of symptomatic gallstones without cholecystectomy - Brittle diabetes or history of severe hypoglycemia unawareness - Previous treatment with a somatostatin analogue



Primary Contact:

Study Chair
Novartis Customer Information
East Hanover

Backup Contact:


Location Contact:

East Hanover, New Jersey 07936
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.